CN102100687B - Application of medicine composition with function of exterminating oral helicobacter pylori - Google Patents
Application of medicine composition with function of exterminating oral helicobacter pylori Download PDFInfo
- Publication number
- CN102100687B CN102100687B CN200910260923A CN200910260923A CN102100687B CN 102100687 B CN102100687 B CN 102100687B CN 200910260923 A CN200910260923 A CN 200910260923A CN 200910260923 A CN200910260923 A CN 200910260923A CN 102100687 B CN102100687 B CN 102100687B
- Authority
- CN
- China
- Prior art keywords
- pylori
- bacterial reproduction
- polylysine
- oral cavity
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an application of polylysine in a preparation of medicine composition with a function of exterminating oral helicobacter pylori. The polylysine and a glycerol monolaurate are simultaneously used, the cure rate of exterminating the oral helicobacter pylori of 83%, also reduces the infection and relapse rate of the gastric helicobacter pylori, does not hurt oral tissues and does not have toxic or side effects.
Description
Technical field:
The present invention relates to field of medicaments, particularly, the present invention relates to polylysine is killed oral cavity pylori medicine in preparation application.
Background technology:
Helicobacter pylori is very big to human beings'health harm, and area, Asia Helicobacter pylori infection crowd is up to more than 75%, China's Tibet region infection population even be higher than 95%.Helicobacter pylori is shape motion in the shape of a spiral in human body, and boring and release toxin cause local gastric tissue to be the ulcer state at the gastric mucosa place, and we are referred to as gastric ulcer.It is countless that asian population was once suffered from the gastric ulcer patient in life, suffers from this sick people's hatefulness for a long time and become cancer, and the rate that cancerates is greatly about about 12%.According to World Health Organization's statistics (2000), the whole world has 800,000 new gastric cancer cases to take place every year, and 640,000 people die from gastric cancer.The case of dying from gastric cancer has 75% to occur in the Asia.Most experts think that the infection stomach function regulating carcinogenesis of pylori has tangible direct relation.
06 year medical science of Nobel prize winner, two Australian doctor Warren are that the stomach pylori causes with Marshall discovery stomach pyloric ulcer.Their first piece of paper is based on 58 patients' gastroscope and pathological section result.This piece paper is to deliver before 25 years, and attention at that time concentrates on gastropyloric inflammation.But increasing in recent years statement of facts, the main source of pylori is in the oral cavity, and the stomach pylorus is nothing but the secondary position.Someone has done 3 years Continuous Tracking and has investigated two groups of crowds in gastropyloric inflammation frequently-occurring disease area, and the 1st group 159 stomach pylorus inflammatory patients are simultaneously with dental disorder, and the 2nd group 200 stomach pylorus inflammatory patients are not sick with dentistry.Behind the antibiotic therapy 1 year, the 1st group of stomach pylorus inflammation relapse rate is 13.2%, and the 2nd group of stomach pylorus inflammation relapse rate was 3.5% (P value＜0.001 of the two is notable difference after statistical procedures).Behind the antibiotic therapy 1 year; The 1st group of stomach pylorus inflammation relapse rate is that 18.4%, the 2 group of stomach pylorus inflammation relapse rate is 2.8% (P＜0.001), behind the antibiotic therapy the 3rd year; The 1st group of stomach pylorus inflammation relapse rate is that 20%, the 2 group of stomach pylorus inflammation relapse rate is 3.8% (P＜0.001).Their conclusion, a) stomach pylorus inflammation is simultaneously organized relapse rate with the patient of dental disorder and is higher than stomach pylorus inflammation but does not have the sick patient's group of dentistry; B) dosage of treatment oral cavity pylori inflammation must be greater than the dosage of treatment stomach pylori inflammation, and recurrence appears in the patient of every stomach pylori inflammation, need transfer to the department of stomatology and make further oral cavity pylori inflammation treatment (B.-S.Sheu; The presence of dental disease can be a risk factor for recurrent Helicobacter pylori infection after eradication therapy:A 3-year follow-up; Endoscopy 39:942-947, DOI:10.1055/s-2007-966787.).
Someone has carried out 4504 patients' research in the U.S., and patient's age was at 20 to 54 years old.They find that gingival pocket (Periodontal Pocket) degree of depth of every oral cavity gingiva surpasses the above person of 5mm, and the pylori antibody positive rate rises in the serum, after statistical procedures, is notable difference.
The sickness rate of stomach pylori disease is very high, and most of patients still can had a relapse behind the pylori eradication therapy.One of reason is that pylori is very ancient antibacterial, just colonizes in the sixth of the twelve Earthly Branches in the human body in the Stone Age, and it has very indomitable survival ability, variation ability and antibiotic resistant rate is risen rapidly.But the main cause that relapse rate is high, the still existence of mouthful source property pylori.After the pylori of gastric was eliminated, oral cavity internal coiling bacillus still can constantly flow into gastric with saliva, and the oral cavity pylori has become the inexhaustible silo of stomach pylori.The source of stomach pylori inflammation is among the oral cavity, along with saliva flows to gastric, causes the stomach Helicobacter pylori inflammation at last.Someone goes on foot and thinks; Pylori colonize between tooth and the gingiva calcareous a kind of crying " biomembrane " (Biofilm) within; This biomembrane consists of barrier one, and it has stopped that medicine gets into this zone; This also is why can eliminate stomach Helicobacter pylori during the medicine routine dose, but fails to kill the reason of oral cavity pylori.
The diagnostic detection of pylori technology comprises gastric mucosa RUT method under the gastroscope at present, gastric mucosa tissue section strain microscopy, and 13 carbon, 14 carbon urea breath methods etc. have obvious blind area to detecting a mouthful source property pylori; Three conventional antibiotic therapies, very little to the effect of oral cavity helicobacter infection.The formation of this predicament and Nobel Prize in medicine in 2006 have certain relation.Two doctors of Australia have found that the pylorus peptic ulcer is that pylori causes, and this finds to explain absolutely clearly that their contribution is huge to the reason of many gastropathy of past.But they have arrived stomach to the attention high concentration of medical circle, even name this pylori by error and to be " stomach pylori ".During in the past 20 years,, Therapeutic Method technological all about the diagnostic detection of pylori all is confined to ignore the dental plaque and the gingival pocket in the field planting ground-oral cavity of another pylori in the sick scope of stomach pylori.Just because such misleading makes us among aspects such as the sick research of pylori, diagnosis and treatment all are in very difficult predicament, perhaps this is a shade under " ring of light ".
Summary of the invention
The object of the present invention is to provide a kind of polylysine to kill the application of oral cavity pylori medicine in preparation, wherein polylysine can use with glyceryl monolaurate simultaneously, and polylysine and glyceryl monolaurate are to have the intravital natural material of people.
Technical scheme of the present invention is following:
Polylysine is killed the application of oral cavity pylori medicine in preparation.
Polylysine and glyceryl monolaurate mix use.
Polylysine is 2-10 with the mixed weight ratio of glyceryl monolaurate: 1.
Polylysine all has the obvious suppression effect to gram positive bacteria and negative bacterium, yeast, mycete, virus etc., is widely used in food fresh keeping.Polylysine is the direct chain polymer of lysine, can in human body, be decomposed into lysine, can be absorbed by human consumption fully, not only has no toxic and side effects, and can be used as a kind of source of lysine.
Glyceryl monolaurate (Glycerol Monolaurate) can exist among the milk of human secretory; It is a kind of natural human milk preservation liquid; It has the ability of certain opposing cause pathogeny imcrobe infection; Add in food, article of everyday use or the cosmetics as food additive, to prolong its shelf-life.
Is safe based on polylysine, glyceryl monolaurate to human body; The inventor expects killing the oral cavity pylori with them; Polylysine, glyceryl monolaurate are mixed and made into pharmaceutical composition by a certain percentage, and the surface of such polylysine and glyceryl monolaurate complex has the positive electricity arc.When the polypeptide of this amino acid structure and pylori were contacted, because screw rod cingula negative electricity arc, pylori just tightly was attached on the key of complex amino acid polypeptide like this.At this moment the physical state of complex is unstable, will produce twist motion between key and the key, at the volley, just tears the cell membrane of the pylori that tightly sticks together with it.After the cell membrane of pylori is torn, just can't survive and death.Because the swing of this polypeptide amino acid complex is a kind of physical property motion purely, pylori can not develop immunity to drugs to this motion.Therefore, this polypeptide amino acid is very powerful to the lethality of pylori, and this is a thinking of the present invention.
Show through clinical trial, sterile test; The mixing of polylysine of the present invention or polylysine and glyceryl monolaurate is used has the purposes of killing the oral cavity pylori, in test the inventor to find the minimum concentration of killing the oral cavity pylori of the pharmaceutical composition that contains polylysine and glyceryl monolaurate be 400mg/100ml.The concentration that polylysine is killed the oral cavity pylori must be higher than 600mg/100ml; The concentration that glyceryl monolaurate is killed the oral cavity pylori must be higher than 400mg/100ml, and the pharmaceutical composition that contains polylysine and glyceryl monolaurate is killed when the concentration of oral cavity pylori is 400mg/100ml and just can be reached satisfied sterilization effect.The sterilization effect of this explanation pharmaceutical composition of the present invention is not the overlapping effect of polylysine and glyceryl monolaurate, but the result of polylysine and glyceryl monolaurate Synergistic.
The beneficial effect of technical scheme of the present invention: pharmaceutical composition of the present invention has the oral cavity of killing pylori purposes; Therefore can be used for preparing the medicine of killing the oral cavity pylori; The cure rate of killing the oral cavity pylori is 83%; Also reduced stomach Helicobacter pylori and infected and relapse rate,, and do not had toxic and side effects not infringement of oral cavity tissue.
The specific embodiment
Embodiment 1
Dual distilled water is heated to 70 ℃ for 10 liters, gets 30 gram polylysines, and 10 gram glyceryl monolaurates add, and mix and stir, and are cooled to room temperature, add Herba Menthae crystal powder 100mg, stir packing, collutory specification: 4g/ liter/bottle.
Embodiment 2
Dual distilled water is heated to 70 ℃ for 10 liters, gets 40 gram polylysines, and 10 gram glyceryl monolaurates add, and mix and stir, and are cooled to room temperature, add Herba Menthae crystal powder 100mg, stir packing, collutory specification: 5g/ liter/bottle.
Embodiment 3
Dual distilled water is heated to 70 ℃ for 10 liters, gets 30 gram polylysines, and 15 gram glyceryl monolaurates add, and mix and stir, and are cooled to room temperature, add Herba Menthae crystal powder 100mg, stir packing, collutory specification: 4.5g/ liter/bottle.
Embodiment 4
Dual distilled water is heated to 70 ℃ for 5 liters, gets 35 gram polylysines, and 5 gram glyceryl monolaurates add, and mix and stir, and are cooled to room temperature, add Herba Menthae crystal powder 50mg, stir packing, oral cavity propellant specification: 400mg/50 milliliter/bottle.
Embodiment 5
Dual distilled water is heated to 70 ℃ for 5 liters, gets 36 gram polylysines, and 4 gram glyceryl monolaurates add, and mix and stir, and are cooled to room temperature, add Herba Menthae crystal powder 50mg, stir packing, oral cavity propellant specification: 400mg/50 milliliter/bottle.
Embodiment 6
Dual distilled water is heated to 70 ℃ for 10 liters, gets 40 gram polylysines, and 4 gram glyceryl monolaurates add, and mix and stir, and are cooled to room temperature, add Herba Menthae crystal powder 100mg, stir packing, collutory specification: 4.4g/ liter/bottle.
Embodiment 7
Dual distilled water is heated to 70 ℃ for 10 liters, gets 50 gram polylysines, and 10 gram glyceryl monolaurates add, and mix and stir, and are cooled to room temperature, add Herba Menthae crystal powder 100mg, stir packing, collutory specification: 6g/ liter/bottle.
Embodiment 8
Dual distilled water is heated to 70 ℃ for 10 liters, gets 60 gram polylysines, and 10 gram glyceryl monolaurates add, and mix and stir, and are cooled to room temperature, add Herba Menthae crystal powder 100mg, stir packing, collutory specification: 10g/ liter/bottle.
Embodiment 9
Dual distilled water is heated to 70 ℃ for 10 liters, gets 60 gram polylysines and adds, and mixes and stirs, and is cooled to room temperature, adds Herba Menthae crystal powder 100mg, stirs packing, collutory specification: 6g/ liter/bottle.
Embodiment 10
Dual distilled water is heated to 70 ℃ for 10 liters, gets 40 gram glyceryl monolaurates and adds, and mixes and stirs, and is cooled to room temperature, adds Herba Menthae crystal powder 100mg, stirs packing, collutory specification: 4g/ liter/bottle.
(1) clinical trial
Experimenter's number: 105.
The experimenter is selected: a) saliva pylori Detection of antigen method (HPS) is determined as positive person; Saliva pylori Detection of antigen method is another utility model patent of the inventor, and it is the noinvasive oral cavity and the helicobacter pylori diagnosis detecting method of new noninvasive.
B) duration of test is not taken antibiotic.
Experimenter's sex: male 52 people, women 53 people.
Tried the range of age: do not limit.
Therapeutic scheme: the positive degree of experimenter's HPS is that (1-2 representes feminine gender through the numerical value on the gold mark colorimetric card; 3-5 representes the weak positive; 6-10 representes the positive; 11-15 representes strong positive) show that subject oral cavity infects the degree of pylori.
Before the treatment: 41 experimenters are strong positive, and 54 experimenters are positive, and 10 experimenters are the weak positive.
Therapeutic process: the experimenter uses the collutory of embodiment 1 to gargle, and does not stop to do the action of gargling simultaneously, and 2 times/day/people, 2 minutes/inferior, 75 days courses of treatment.
Therapeutic outcome: 87 experimenters are changed feminine gender fully into, and 83% for curing, and 15 experimenter people are changed the weak positive into, and 14.2% for being clearly better, and 3 experimenters are positive, and 2.8% is invalid.
After most experimenters treated through the collutory that uses embodiment 1, the helicobacter infection positive changed feminine gender into from the oral cavity, and cure rate is 83%.But still have 14.2% experimenter for the weak positive, this possibly be that the compliance of treatment is poor, just the experimenter maybe be not according to the rules time, number of times gargle, have 2.8% experimenter invalid in addition.
(2) sterile test
The pylori culture bottle is placed in the agitator, and frequency 30 times/minute/24 hours keeps 9% oxygen in the pylori culture bottle, guarantees in each culture bottle pylori content more than 500,000, with this as matched group.The pharmaceutical composition that contains polylysine and glyceryl monolaurate that in matched group, adds varying number; The weight ratio of said polylysine and said glyceryl monolaurate is 5: 1; See the following form 1,7 days incubated at room temperature time, the pharmaceutical composition sterilization effect of variable concentrations behind the observation adding pharmaceutical composition; Each concentration repeats 10 tests, and the result sees table 1.
Table 1 sterile test
Result of the test: pharmaceutical composition of the present invention has the effect of killing the oral cavity pylori in the above concentration of 400mg/100ml.
(3) sterile test of polylysine
The pylori culture bottle is placed in the agitator, and frequency 30 times/minute/24 hours keeps 9% oxygen in the pylori culture bottle, guarantees in each culture bottle pylori content more than 500,000, with this as matched group.The polylysine that in matched group, adds varying number, 7 days incubated at room temperature time, the sterilization effect of the polylysine of variable concentrations behind the observation adding polylysine, each concentration repeats 10 tests, and the result sees table 2.
Table 2 polylysine sterile test
Result of the test: the sterilization concentration of polylysine must be higher than 600mg/100ml.
(4) sterile test of glyceryl monolaurate
The pylori culture bottle is placed in the agitator, and frequency 30 times/minute/24 hours keeps 9% oxygen in the pylori culture bottle, guarantees in each culture bottle pylori content more than 500,000, with this as matched group.The glyceryl monolaurate that in matched group, adds varying number, 7 days incubated at room temperature time, the sterilization effect of the glyceryl monolaurate of variable concentrations behind the observation adding glyceryl monolaurate, each concentration repeats 10 tests, and the result sees table 3.
Table 3 glyceryl monolaurate sterile test
Result of the test: glyceryl monolaurate sterilization concentration must be higher than 400mg/100ml.
(5) optical density test
The pylori culture bottle is placed in the agitator, and frequency 30 times/minute/24 hours keeps 9% oxygen in the pylori culture bottle, guarantees in each culture bottle pylori content more than 500,000, with this as matched group.The weight ratio that in matched group, adds polylysine and glyceryl monolaurate respectively is 3: 1 pharmaceutical composition, polylysine, a glyceryl monolaurate; 7 days incubated at room temperature time; Measure optical density; 10 optical density of every group of replication, optical density numerical value are got the meansigma methods of measuring numerical value for ten times, and the result sees table 4.
The test of table 4 optical density
Result of the test: compare with matched group; The weight ratio of polylysine and glyceryl monolaurate is that 3: 1 the optical density numerical value of pharmaceutical composition (400mg/100ml), polylysine (600mg/100ml), glyceryl monolaurate (400mg/100ml) is low; And that the weight ratio of polylysine and glyceryl monolaurate is the optical density numerical value of optical density numeric ratio polylysine (600mg/100ml), glyceryl monolaurate (400mg/100ml) of 3: 1 pharmaceutical composition (400mg/100ml) is low nearly one times, and the weight ratio that proves polylysine and glyceryl monolaurate thus is sterilization effect the best of 3: 1 pharmaceutical composition (400mg/100ml).OD numerical value is low to show there is not bacterial growth.
(6) stability test
1) thimble test: observe the sterilization effect of 37 ℃, 38 ℃, 39 ℃, 40 ℃ four temperature spot pharmaceutical compositions of the present invention, each temperature spot repeats 5 tests, and the result sees table 5.
Table 5 thimble test
| Temperature | Concentration | The pylori incubation time (my god) | Pylori is cultivated |
| 37℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 37℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 37℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 37℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 37℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 38℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 38℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 38℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 38℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 38℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 39℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 39℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 39℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 39℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 39℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 40℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 40℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 40℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 40℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 40℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
Result of the test: variations in temperature does not have influence to embodiment 1 sterilization effect.
2) low-temperature stability test: observe the sterilization effect of 3 ℃, 6 ℃, 10 ℃, 15 ℃ four temperature spot pharmaceutical compositions of the present invention, each temperature spot repeats 5 tests, and the result sees table 6.
The test of table 6 low-temperature stability
| Temperature | Concentration | The pylori incubation time (my god) | Pylori is cultivated |
| 3℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 3℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 3℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 3℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 3℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 10℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 10℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 10℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 10℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 10℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 15℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 15℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 15℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 15℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
| 15℃ | Embodiment 1 | 7 | There is not bacterial reproduction |
Result of the test: variations in temperature does not have influence to embodiment 1 sterilization effect.
(7) vibration test
May be vibrated and rocked at collutory described in the transportation, oral cavity propellant, Chewing gum or capsule; We have designed under 10 times, 30 times, 60 times situation of per minute vibration, 15 days time, observe embodiment 1 sterilization effect; Every kind of vibration situation repeats 5 tests, and the result sees table 7.
Table 7 vibration test
| Vibration number | Concentration | The pylori incubation time (my god) | Pylori is cultivated |
| 10 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 10 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 10 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 10 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 10 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 30 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 30 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 30 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 30 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 30 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 60 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 60 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 60 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 60 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
| 60 times/minute | Embodiment 1 | 7 | There is not bacterial reproduction |
Result of the test: vibration does not have influence to embodiment 1 sterilization effect.
(8) degradation
Consider the shelf-life one year after said collutory, oral cavity propellant, Chewing gum or the capsule manufacture, we observed 3rd month, 6 months, 9 months and 12 months embodiment 1 sterilization effects, and each storage life repeats 5 tests, and the result sees table 8.
Table 8 degradation
| Month number | Concentration | The pylori incubation time (my god) | Pylori is cultivated |
| 3 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 3 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 3 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 3 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 3 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 6 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 9 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 9 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 9 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 9 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 9 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 12 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 12 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 12 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 12 months | Embodiment 1 | 7 | There is not bacterial reproduction |
| 12 months | Embodiment 1 | 7 | There is not bacterial reproduction |
Result of the test: store 12 months embodiment 1 afterwards and still have good sterilization functions.
(9) toxicity test
Subjects: white mice is some;
Process of the test: we are mixed in pharmaceutical composition of the present invention in the food, the feeding white mice, and by the body weight of white mice, we give following dosage: 4 gram/kilograms, 5 gram/kilograms.
Result of the test: white mice has been swallowed behind the pharmaceutical composition of the present invention of 4 gram/kilograms or 5 gram/kilogram dosage, and their diet, motion are normal, any untoward reaction do not occur, explain that pharmaceutical composition of the present invention is safe to human body.
Claims (3)
1. polylysine is killed the application of oral cavity pylori medicine in preparation.
2. application according to claim 1 is characterized in that: polylysine and glyceryl monolaurate mix use.
3. application according to claim 2 is characterized in that: polylysine is 2-10 with the mixed weight ratio of glyceryl monolaurate: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910260923A CN102100687B (en) | 2009-12-17 | 2009-12-17 | Application of medicine composition with function of exterminating oral helicobacter pylori |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910260923A CN102100687B (en) | 2009-12-17 | 2009-12-17 | Application of medicine composition with function of exterminating oral helicobacter pylori |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102100687A CN102100687A (en) | 2011-06-22 |
| CN102100687B true CN102100687B (en) | 2012-10-03 |
Family
ID=44153887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910260923A Expired - Fee Related CN102100687B (en) | 2009-12-17 | 2009-12-17 | Application of medicine composition with function of exterminating oral helicobacter pylori |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102100687B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111184858A (en) * | 2020-03-16 | 2020-05-22 | 南京康容健康科技有限公司 | A preparation for preventing and treating helicobacter pylori |
| CN111568919A (en) * | 2020-05-19 | 2020-08-25 | 上海中砥生物科技有限公司 | A preparation containing chitosan oligosaccharide for resisting helicobacter pylori |
| CN112546232A (en) * | 2020-12-30 | 2021-03-26 | 南京康容健康科技有限公司 | A preparation for preventing helicobacter pylori infection |
| CN115252469A (en) * | 2022-08-24 | 2022-11-01 | 张翠平 | Bacteriostatic liquid capable of inhibiting helicobacter pylori and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207045A (en) * | 1996-01-05 | 1999-02-03 | Ambi股份有限公司 | Nisin in combination with glycerol monolaurate active against helicobacter |
| JP2009132702A (en) * | 2007-11-06 | 2009-06-18 | Dentoro Chem:Kk | Antibacterial aqueous solution and production method thereof |
-
2009
- 2009-12-17 CN CN200910260923A patent/CN102100687B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207045A (en) * | 1996-01-05 | 1999-02-03 | Ambi股份有限公司 | Nisin in combination with glycerol monolaurate active against helicobacter |
| JP2009132702A (en) * | 2007-11-06 | 2009-06-18 | Dentoro Chem:Kk | Antibacterial aqueous solution and production method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102100687A (en) | 2011-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102100687B (en) | Application of medicine composition with function of exterminating oral helicobacter pylori | |
| CN113577218A (en) | Inactivated probiotic traditional Chinese medicine composition for inhibiting helicobacter pylori and preparation method and application thereof | |
| CN107106600A (en) | Utilize the medical composition of conbustion synthesis material, blood processor, cosmetics and diet product | |
| ES2340603T3 (en) | BACTERIAL CULTURE WITH SUPPRESSING EFFECT OF THE DEVELOPMENT OF DERMATITIS AND ACCELERATOR OF WOUND AND PRODUCT CICATRIZATION USING IT. | |
| CN111568919A (en) | A preparation containing chitosan oligosaccharide for resisting helicobacter pylori | |
| CN110384725A (en) | A kind of preparation of Chinese traditional medicine composition and its activity extract for adjusting oral cavity flora | |
| WO2010000207A1 (en) | A natural allicin tablet and preparation method thereof | |
| CN109985069A (en) | Probiotic composition and application thereof | |
| RU2708624C1 (en) | Method of treating periodontitis | |
| CN102311932A (en) | Lactobacillus salivarius for improving bacterial population in oral cavity and health-care composition thereof | |
| CA2488384A1 (en) | Natural herbal antibiotic for the treatment of the infections of the upper respiratory system and various diseases in the body | |
| KR100980254B1 (en) | Composition for helicobactor pylori bactericide causing gastritis or peptic ulser coprising polylysine and glycerol monolaurate | |
| RU2751810C1 (en) | Method for treatment of chronic periodontitis | |
| CN107897512A (en) | It is a kind of to be used to improve enteron aisle health-care agent of chicken intestinal health and preparation method thereof | |
| CN108714215A (en) | A kind of mouth sprays and its preparation method and application | |
| RU2708615C1 (en) | Method of treating chronic periodontitis | |
| Bernoville | Diseases of the Respiratory & Digestive System of Children | |
| Рахимов et al. | RESULTS OF TREATMENT OF UNCOMPLICATED LOWER JAW FRACTURES | |
| CN106236645A (en) | A kind of natural child's collutory | |
| Nieder et al. | Medicinal uses of soil components, geophagia and podoconiosis | |
| RU2751809C1 (en) | Method for treatment of periodontitis | |
| RU2247148C2 (en) | Strain of microorganism lactobacillus plantarum p4, strain of microorganism lactobacillus buchneri p0 and probiotic preparation based on thereof for correction of dysbacteriosis of different etiology in humans and animals | |
| RU2810419C1 (en) | Method of chronic periodontitis treatment | |
| CN117298184B (en) | Composition for treating constipation and halitosis, and preparation method and application thereof | |
| CN104940438A (en) | Chinese herbal medicine extract and toothpaste for preventing and treating childhood caries, and application of Chinese herbal medicine extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121003 Termination date: 20191217 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |